Navigation Links
CryoLife Completes Acquisition of Hemosphere
Date:5/16/2012

ATLANTA, May 16, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device company focused on cardiac and vascular surgery, announced today that it has completed its previously announced acquisition of Hemosphere, Inc.  Hemosphere developed and markets the HeRO (Hemodialysis Reliable Outflow) Graft, a proprietary graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with limited access options and central venous obstruction.

CryoLife will begin the integration of the Hemosphere business immediately and expects to begin training its sales force on the HeRO Graft in the second quarter 2012, followed by a launch of the HeRO Graft in the United States through its 28-person cardiovascular sales team late in the third quarter  2012.

Steven G. Anderson, president and chief executive officer of CryoLife, said, "The talented team at Hemosphere has developed a unique technology for end-stage renal disease hemodialysis patients that are otherwise faced with sub-optimal treatment alternatives. We believe that this acquisition is well in-line with our cardiovascular focus and look forward to integrating the business and collaborating with the Hemosphere team to train our sales reps on the HeRO Graft."

About CryoLife

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada.  CryoLife's CryoValve® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves.  CryoLife's CryoPatch® SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of the right ventricular outflow tract (RVOT), which is a surgery commonly performed in children with congenital heart defects, such as Tetralogy of Fallot, Truncus Arteriosus, and Pulmonary Atresia.  CryoPatch SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk, and pulmonary branch.  CryoLife's BioGlue® Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels.  BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair and was recently approved in Japan for use in the repair of aortic dissections.  CryoLife, through its subsidiary Cardiogenesis Corporation, specializes in the treatment of cardiovascular disease and the sale of devices that treat severe angina.  Its market leading FDA-approved Holmium: YAG laser system and single use fiber-optic delivery systems are used to perform a surgical procedure known as Transmyocardial Revascularization (TMR).  CryoLife distributes PerClot®, an absorbable powder hemostat, in the European Community.  CryoLife's BioFoam Surgical Matrix is CE marked in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical. 

Statements made in this press release that look forward in time or that express management's beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements reflect the views of management at the time such statements are made and are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations.  These statements include those regarding our plans and estimated timing related to the integration of HeRO Graft sales into our business, the training of our sales force on the HeRO Graft and the launch of HeRO Graft sales in the United States.  These risks and uncertainties include that we may not be able to effectively leverage our existing relationships and infrastructure to increase HeRO Graft sales.  HeRO Graft sales are dependent on physician and patient acceptance, among other things, and competitors may be able to develop and successfully market competing products.  As with most acquisitions, the successful integration of Hemosphere's business into ours may take longer and prove more costly than expected, and we may experience currently unforeseen difficulties related to the HeRO Graft product, the ability of our sales force to market HeRO Graft, and physician training and patient acceptance of HeRO Graft.  If we experience problems that slow the integration of Hemosphere's business into our business, then we will not be able to reap the benefits of this transaction in a timely fashion, if at all.  We may also inherit unforeseen risks and uncertainties related to Hemosphere's business, particularly if the information received by CryoLife during the due diligence phase of this acquisition is incomplete or inaccurate.  Successful HeRO Graft sales may require the formation of new relationships and contracts, and there is no guarantee that we will be able to maintain existing HeRO Graft sales and/or expand into new territories.  International sales growth is also dependent on physician and patient acceptance, along with international economic conditions, foreign exchange rates and regulatory approvals in various jurisdictions.  Even if we experience successful sales growth for HeRO Graft, our margins would be impacted if we experience increased costs related to the manufacturing and distribution of HeRO Graft.  HeRO Graft may not continue to experience expanding reimbursement rates in the U.S., and if patients are not able to receive reimbursement from their insurance providers for this product, sales could be materially impacted.  HeRO Graft may not continue to provide the anticipated medical benefits.  If the medical profession and patients do not perceive HeRO Graft to be a safe and effective product, our sales would be materially impacted and we may experience lawsuits as a result.  Our plans with respect to the allocation of future resources to the development and growth of HeRO Graft sales are subject to change at the discretion of management based on CryoLife's business needs at the time.  Any of these risks could cause the financial impact of the acquisition to be less advantageous than currently anticipated.  These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for the year ended December 31, 2011.  CryoLife does not undertake to update its forward-looking statements.

For additional information about the company, visit CryoLife's website: www.cryolife.com.

Contacts:


CryoLife

D. Ashley Lee

Executive Vice President, Chief Financial Officer

 and Chief Operating Officer

Phone: 770-419-3355

The Ruth Group

Nick Laudico / Zack Kubow

646-536-7030 / 7020

nlaudico@theruthgroup.com

zkubow@theruthgroup.com

 


'/>"/>
SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
2. CryoLife Announces Release Date and Teleconference Call Details for 2011 Fourth Quarter and Year End Financial Results
3. CryoLife Enhances Management Team with Promotions
4. CryoLife to Present at 6th Annual Canaccord Genuity Cardiovascular, Aesthetics & Metabolic Disorders Conference
5. CryoLife to Present at 23rd Annual Piper Jaffray Health Care Conference
6. CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011
7. CryoLife Initiates Enrollment in U.S. Clinical Trial for BioFoam®
8. CryoLife Announces Release Date and Teleconference Call Details for 2011 Third Quarter Financial Results
9. CryoLife Provides Update on ValveXchange®, Inc. Investment
10. CryoLife Reports Record Revenues for the Second Quarter and First Six Months of 2011
11. CryoLife Announces Release Date and Teleconference Call Details for 2011 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Research and Markets has announced the addition of the ... Opportunity Analysis and Industry Forecast, 2014-2022" report to their offering. ... Vital signs monitoring market size ... million by 2022, growing at a CAGR of 5.8% from 2016 to ... leading regional market in global vital signs monitoring devices industry. The blood ...
(Date:1/18/2017)... -- Adaptive Sound Technologies, Inc. (ASTI), the leading supplier of ... Place Nashville/Downtown to deliver the best sleep experience for ... in over two hundred of its guest rooms. ... having a great stay is sleeping well," said ... "We,re pleased to be able to offer our guests ...
(Date:1/18/2017)... FALLS, N.J. , Jan. 18, 2017   ... ), a biotechnology company specializing in the development and ... of damaged tissues and organs, recently reported the Company,s ... milestones for 2017. As the Company described ... has been a year of substantial accomplishments. The Company,s ...
Breaking Medicine Technology:
(Date:1/19/2017)... Los Angeles, California (PRWEB) , ... January 19, ... ... at the hands of a doctor who administered fillers that resulted in severe ... her unprecedented case was taken on by doctors at UCLA Medical Center, who ...
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... ... Tranquility acoustic and privacy panel system. , The Tranquility privacy panel system ... a collaborative office environment. Tranquility panels help reduce noise and provide the visual ...
(Date:1/19/2017)... ... January 19, 2017 , ... Sam & Associates Insurance Agency, a full service ... in the California Bay Area, is launching a charity drive to raise awareness of ... disease is the primary killer of adult men and women in America, and is ...
(Date:1/19/2017)... ... January 19, 2017 , ... For the third ... New Jersey and the surrounding area, is inaugurating a charity event to ... commonly known as Lou Gehrig's disease or motor neurone disease, is a deadly ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... the 2017 Spring Create Real Impact contest from Impact Teen Drivers and California ... http://www.createrealimpact.com . , Educational grants totaling $15,000 will be awarded for ...
Breaking Medicine News(10 mins):